Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKLB1028 + cytarabine + daunorubicin
- Development stage
- Phase 2
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination regimen consisting of **SKLB1028**, an oral small molecule multi-kinase inhibitor (targeting FLT3, EGFR, and Abl kinases), **cytarabine**, a nucleoside analog antimetabolite, and **daunorubicin**, an anthracycline antibiotic. SKLB1028 is in development primarily for acute myeloid leukemia (AML) with FLT3 mutations, showing activity in FLT3-ITD AML models, and is being investigated in clinical trials in combination with standard AML therapy (the "7+3" regimen: cytarabine and daunorubicin) for FLT3-mutated AML. The combination aims to leverage targeted inhibition of FLT3-driven signaling and standard cytotoxic chemotherapy for synergistic antileukemic activity[1][3][5][7].
- Other names
- SKLB-1028 + cytarabine + daunorubicinruserontinib + cytarabine + daunorubicin
02
Targets
ABL2 (ABL proto-oncogene 2, non-receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)LYN (LYN proto-oncogene, Src family tyrosine kinase)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on SKLB1028 + cytarabine + daunorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKLB1028 + cytarabine + daunorubicin.